Solving

The Unsolved.

Developing musculoskeletal therapeutics for the most underlooked conditions.

Repetitive Strain Injuries

$120 BILLION

indirect and direct expenses annually in America alone.

OVER 10%

of adults have a form of repetitive strain injury.

0

pharmacological interventions indicated to treat RSIs.

Developing impactful therapeutics in some of the most underlooked conditions.

Best-in-class therapeutics to solve RSIs such as carpal tunnel syndrome and tendinopathy.

Product Indications Discovery Pre-Clinical Phase I Phase II Phase III
KHRX-101 Carpal Tunnel Syndrome
Tendinopathy
KHRX-102 Carpal Tunnel Syndrome
Tendinopathy
KHRX-103 Osteoarthritis
Rheumatoid Arthritis
Discovery Programs Discovery

Innovation advancing humanity.

Therapeutic Development

Clinical Trial Technologies

Drug Discovery

Khan Sciences is developing cutting edge therapeutics, and the technologies around them.

If you'd like to say hi, or are interested in learning more, you can find our contact details below.

Contact Us

Reach out to us below.

Email
support@khansciences.com
Office
Washington, DC